Sotorasib Combo vs Pembrolizumab Combo for Advanced Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing two different drug combinations with chemotherapy to see which helps cancer patients live longer without their disease getting worse. One combination includes sotorasib, which targets cancer mutations, and the other includes pembrolizumab, which helps the immune system fight cancer. Pembrolizumab has been shown to improve overall survival in various cancers when combined with chemotherapy.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the combination of Sotorasib and Pembrolizumab safe for humans?
Pembrolizumab, also known as Keytruda, has been studied in various trials for lung cancer and has shown a safety profile with fewer treatment-related side effects compared to traditional chemotherapy. While specific safety data for the combination with Sotorasib is not provided, Pembrolizumab alone has been generally safe in humans.12345
How is the Sotorasib and Pembrolizumab drug combination unique for advanced lung cancer?
The Sotorasib and Pembrolizumab combination is unique because it combines Sotorasib, a targeted therapy that specifically inhibits a mutation in the KRAS gene, with Pembrolizumab, an immunotherapy that helps the immune system attack cancer cells. This combination targets both the genetic mutation and enhances the immune response, offering a novel approach compared to standard chemotherapy or immunotherapy alone.16789
What data supports the effectiveness of the drug pembrolizumab in treating advanced lung cancer?
Research shows that pembrolizumab significantly improves survival in patients with advanced non-small-cell lung cancer (NSCLC) compared to traditional chemotherapy, especially in those with high levels of a protein called PD-L1. This suggests that pembrolizumab can be an effective treatment option for this type of lung cancer.19101112
Who Is on the Research Team?
MD
Principal Investigator
Amgen
Are You a Good Fit for This Trial?
This trial is for adults with advanced non-squamous Non-Small Cell Lung Cancer (NSCLC) that has a specific mutation (KRAS p. G12C) and no PD-L1 expression. They should not have had cancer treatment in the metastatic setting, be relatively fit (ECOG ≤ 1), and able to take oral medication.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either sotorasib with platinum doublet chemotherapy or pembrolizumab with platinum doublet chemotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Pembrolizumab
- Sotorasib
Pembrolizumab is already approved in United States, European Union, United Kingdom for the following indications:
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
- Melanoma
- Non-small cell lung cancer (NSCLC)
- Urothelial carcinoma
- Colorectal cancer
- Gastric cancer
- Hepatocellular carcinoma
- Renal cell carcinoma
- Cervical cancer
- Endometrial carcinoma
- Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS ≥1
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amgen
Lead Sponsor
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London